On October 8, 10x Genomics, Inc. declined 5.26% in regular trading, trading at $71.6/share with Turnover of $27.5519 million.

The decline came despite the company's announcement of a multi-project research collaboration with Fred Hutchinson Cancer Center, which failed to lift market sentiment. The first project will use the Flex Apex and Xenium platforms to identify treatment-response biomarkers in advanced bladder cancer, while the second will use Flex Apex to assess single-cell analysis for improving residual disease detection in acute myeloid leukemia after treatment. The stock had already fallen 7.6% on the day the collaboration was announced, reflecting persistent selling pressure.

Within the Life Sciences Tools & Services sector, Tempus AI fell 4.57%, Thermo Fisher Scientific fell 2.87%, Illumina fell 3.48%, Danaher fell 2.06%, and Agilent fell 2.63%. The broad-based weakness in technical platform names suggests sector-wide de-rating rather than company-specific drivers.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems. Its single cell solutions run on Chromium instruments, while its spatial offerings include the Visium and Atera platforms.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)